Osteoporosis in HIV-infected patient
DOI:
https://doi.org/10.14456/dcj.2014.9Keywords:
Osteoporosis, bone mineral density, HIVAbstract
As the HIV-infected population has life expectancy close to that of the normal population due to effective highly active antiretroviral therapy, low bone mineral density are becoming more common problems. Osteoporosis and osteopenia predispose to an increased risk of fracture that is the serious complication. There are many HIV-associated risk factors including HIV infection, hepatitis c infection, antiretroviral therapy particularly tenofovir, other medication used in the treatment of the complication of HIV and alteration in hormone and calcium. Therefore HIV infection is the important risk factor for osteoporosis and there are recommendation for screening for osteoporosis in HIV-infected postmenopausal women and men starting at 50 years of age. The therapy consists of lifestyle changes and pharmacologic medication such as bisphosphonate, calcium and vitamin D. Awareness of disease and risk factors is important for prevention and early diagnosis that lead to further holistic management.
Downloads
Download data is not yet available.
References
1. Borderi M, Gibellini D, Vescini F, De Crignis E, Cimatti L, Biagetti C, et al. Metabolic bone disease in HIV infection. AIDS 2009;23:1297.
2. World Health Organization. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. Report of a WHO Study Group. World Health Organization technical report series 1994;843:1-129.
3. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006;20:2165.
4. Bonjoch A, Figueras M, Estany c, Perez- Alvarez N, Rosales J, del Rio L, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 2010;24:2827.
5. Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008;22:395.
6. Sittibusaya C, Manosuthi W. Evaluation of bone structure by quantitative ultrasound at Calcaneous in HIV patients at Bumrasnaradura Institute. Disease Control Journal 2004;3:187.
7. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non - HIV- infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008;93:3499.
8. McComsey GA, Huang JS, Woolley IJ, Young B, Sax PE, Gerber M, et al. Fragility fractures in HIV-infected patients: need for better under-standing of diagnosis and management. J Int Assoc Physicians AIDS Care (Chic) 2004;3:86.
9. Stephens EA, Das R, Madge S, Barter J, Johnson MA. Symptomatic osteoporosis in two young HIV-positive African women. AIDS 1999;13:2605.
10. Martin K, Lawson-Ayayi S, Miremont-Salame G, Blaizeau MJ, Balestre E, Lacoste D, et al. Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitaine cohort (1999- 2002). HIV Med 2004;5:421.
11. Young B, Dao CN, Buchacz K, Baker R, Brooks JT; HIV Outpatient Study (HOPS) investigators increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011;52:1061.
12. Lo Re V 3rd, Volk J, Newcomb cw, Yang YX, Freeman CP, Hennessy S, et al. Risk of hip fracture associated with hepatitis c virus infection and hepatitis c/human immunodeficiency virus coinfection. Hepatology 2012;56:1688.
13. Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, et al. Bone mineral density remains stable in HA ART- treated HIV-infected men over 2 years. Clin Endocrinol (Oxf). 2007;67:270-5.
14. Jacobson DL, spiegelman D, Knox TK, Wilson IB. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr 2008;49:298.
15. Womack JA, Goulet JL, Gibert C, Brandt CA, Skanderson M, Gulanski B, et al. Physiologic frailty and fragility fracture in HIV-infected male veterans. Clin Infect Dis 2013;56:1498.
16. Mueller NJ, Fux CA, Ledergerber B, Elzi L, Schmid P, Dang T, et al. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS 2010;24: 1127.
17. Sherwood JE, Mesner OC, Weintrob AC, Hadigan CM, Wilkins KJ, Crum-Cianflone NF, et al. Vitamin D deficiency and its association with low bone mineral density, HIV-related factors, hospitalization, and death in a predominantly black HIV-infected cohort. Clin Infect Dis 2012;55:1727.
18. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging in-sights into the pathophysiology of osteoporosis. N Engl J Med 1995;332:305.
19. Gibellini D, De Crignis E, Ponti C, Cimatti L, Borderi M, Tschon M, et al. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol 2008;80:1507.
20. Yin MT, Shi Q, Hoover DR, Anastos K, Sharma A, Young M, et ฟ. Fracture incidence in HIV- infected women: results from the women's Interagency HIV Study. AIDS 2010;24:2679.
21. Collier J. Bone disorders in chronic liver disease. Hepatology 2007;46:1271.
22. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009;23:817.
23. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009;51:554.
24. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010;51:963.
25. Mulligan K, Harris DR, Emmanuel P, Fielding RA, Worrell C, Kapogiannis BG, et al. Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B. Clin Infect Dis 2012;55:461.
26. Grant PM, Kitch D, McComsey GA, Dube MP, Haubrich R, Huang J, et al. Low baseline CD4 + count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis 2013;57:1483.
27. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 2012;26:825.
28. Gallant JE, Staszewski S, Pozniak AL, Dejesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vsstavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292: 191.
29. Earle KE, Seneviratne T, Shaker J, Shoback D. Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res 2004;19:714.
30. Perrot S, Aslangul E, Szwebel T, Caillat-Vigneron N, Le Jeunne c. Bone pain due to fractures revealing osteomalacia related to tenofovir- induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient. J Clin Rheumatol 2009;15:72.
31. Pedrazzoni M, Vescovi PP, Maninetti L, Michelini M, Zaniboni G, Pioli GP, et al. Effects of chronic heroin abuse on bone and mineral metabolism. Acta Endocrinol (Copenh) 1993; 129:42.
32. Aukrust P, Haug CJ, Ueland T, Lien E, Muller F, Espevik T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999;84:145.
33. Heilman P, Albert J, Gidlund M, Klareskog L, Rastad J, AkerstrOm G, et al. Impaired parathyroid hormone release in human immunodeficiency virus infection. AIDS Res Hum Retroviruses 1994;10:391.
34. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 2010;51:937.
35. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2014;58:1.
36. Garcia-AparicioAM, Munoz Fernandez S, Gonzalez J, Arribas JR, Pena JM, Vazquez JJ, et al. Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol 2006;25:537.
37. Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, Sweep FC, Hermus AR, Bosch ME, et al. Vitamin D deficiency among HIV type 1 - infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008;24:1375.
38. Mondy K, Powderly WG, Claxton SA, Yarasheski KH, Royal M, Stoneman JS, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/ osteoporosis associated with HIV in-fection. J Acquir Immune Defic Syndr 2005;38:426.
39. McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007;21:2473.
40. Huang J, Meixner L, Fernandez S, McCutchan JA. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 2009;23:51.
41. Bolland MJ, Grey AB, Home AM, Briggs SE, Thomas MG, Ellis-Pegler RB, et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab 2007;92:1283.
42. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academies Press; 2010.
2. World Health Organization. Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. Report of a WHO Study Group. World Health Organization technical report series 1994;843:1-129.
3. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006;20:2165.
4. Bonjoch A, Figueras M, Estany c, Perez- Alvarez N, Rosales J, del Rio L, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS 2010;24:2827.
5. Cazanave C, Dupon M, Lavignolle-Aurillac V, Barthe N, Lawson-Ayayi S, Mehsen N, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS 2008;22:395.
6. Sittibusaya C, Manosuthi W. Evaluation of bone structure by quantitative ultrasound at Calcaneous in HIV patients at Bumrasnaradura Institute. Disease Control Journal 2004;3:187.
7. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non - HIV- infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008;93:3499.
8. McComsey GA, Huang JS, Woolley IJ, Young B, Sax PE, Gerber M, et al. Fragility fractures in HIV-infected patients: need for better under-standing of diagnosis and management. J Int Assoc Physicians AIDS Care (Chic) 2004;3:86.
9. Stephens EA, Das R, Madge S, Barter J, Johnson MA. Symptomatic osteoporosis in two young HIV-positive African women. AIDS 1999;13:2605.
10. Martin K, Lawson-Ayayi S, Miremont-Salame G, Blaizeau MJ, Balestre E, Lacoste D, et al. Symptomatic bone disorders in HIV-infected patients: incidence in the Aquitaine cohort (1999- 2002). HIV Med 2004;5:421.
11. Young B, Dao CN, Buchacz K, Baker R, Brooks JT; HIV Outpatient Study (HOPS) investigators increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011;52:1061.
12. Lo Re V 3rd, Volk J, Newcomb cw, Yang YX, Freeman CP, Hennessy S, et al. Risk of hip fracture associated with hepatitis c virus infection and hepatitis c/human immunodeficiency virus coinfection. Hepatology 2012;56:1688.
13. Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, et al. Bone mineral density remains stable in HA ART- treated HIV-infected men over 2 years. Clin Endocrinol (Oxf). 2007;67:270-5.
14. Jacobson DL, spiegelman D, Knox TK, Wilson IB. Evolution and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr 2008;49:298.
15. Womack JA, Goulet JL, Gibert C, Brandt CA, Skanderson M, Gulanski B, et al. Physiologic frailty and fragility fracture in HIV-infected male veterans. Clin Infect Dis 2013;56:1498.
16. Mueller NJ, Fux CA, Ledergerber B, Elzi L, Schmid P, Dang T, et al. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS 2010;24: 1127.
17. Sherwood JE, Mesner OC, Weintrob AC, Hadigan CM, Wilkins KJ, Crum-Cianflone NF, et al. Vitamin D deficiency and its association with low bone mineral density, HIV-related factors, hospitalization, and death in a predominantly black HIV-infected cohort. Clin Infect Dis 2012;55:1727.
18. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging in-sights into the pathophysiology of osteoporosis. N Engl J Med 1995;332:305.
19. Gibellini D, De Crignis E, Ponti C, Cimatti L, Borderi M, Tschon M, et al. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol 2008;80:1507.
20. Yin MT, Shi Q, Hoover DR, Anastos K, Sharma A, Young M, et ฟ. Fracture incidence in HIV- infected women: results from the women's Interagency HIV Study. AIDS 2010;24:2679.
21. Collier J. Bone disorders in chronic liver disease. Hepatology 2007;46:1271.
22. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009;23:817.
23. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009;51:554.
24. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis 2010;51:963.
25. Mulligan K, Harris DR, Emmanuel P, Fielding RA, Worrell C, Kapogiannis BG, et al. Low bone mass in behaviorally HIV-infected young men on antiretroviral therapy: Adolescent Trials Network Study 021B. Clin Infect Dis 2012;55:461.
26. Grant PM, Kitch D, McComsey GA, Dube MP, Haubrich R, Huang J, et al. Low baseline CD4 + count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis 2013;57:1483.
27. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 2012;26:825.
28. Gallant JE, Staszewski S, Pozniak AL, Dejesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vsstavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004;292: 191.
29. Earle KE, Seneviratne T, Shaker J, Shoback D. Fanconi's syndrome in HIV+ adults: report of three cases and literature review. J Bone Miner Res 2004;19:714.
30. Perrot S, Aslangul E, Szwebel T, Caillat-Vigneron N, Le Jeunne c. Bone pain due to fractures revealing osteomalacia related to tenofovir- induced proximal renal tubular dysfunction in a human immunodeficiency virus-infected patient. J Clin Rheumatol 2009;15:72.
31. Pedrazzoni M, Vescovi PP, Maninetti L, Michelini M, Zaniboni G, Pioli GP, et al. Effects of chronic heroin abuse on bone and mineral metabolism. Acta Endocrinol (Copenh) 1993; 129:42.
32. Aukrust P, Haug CJ, Ueland T, Lien E, Muller F, Espevik T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab 1999;84:145.
33. Heilman P, Albert J, Gidlund M, Klareskog L, Rastad J, AkerstrOm G, et al. Impaired parathyroid hormone release in human immunodeficiency virus infection. AIDS Res Hum Retroviruses 1994;10:391.
34. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis 2010;51:937.
35. Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2014;58:1.
36. Garcia-AparicioAM, Munoz Fernandez S, Gonzalez J, Arribas JR, Pena JM, Vazquez JJ, et al. Abnormalities in the bone mineral metabolism in HIV-infected patients. Clin Rheumatol 2006;25:537.
37. Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, Sweep FC, Hermus AR, Bosch ME, et al. Vitamin D deficiency among HIV type 1 - infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008;24:1375.
38. Mondy K, Powderly WG, Claxton SA, Yarasheski KH, Royal M, Stoneman JS, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/ osteoporosis associated with HIV in-fection. J Acquir Immune Defic Syndr 2005;38:426.
39. McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007;21:2473.
40. Huang J, Meixner L, Fernandez S, McCutchan JA. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 2009;23:51.
41. Bolland MJ, Grey AB, Home AM, Briggs SE, Thomas MG, Ellis-Pegler RB, et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab 2007;92:1283.
42. Institute of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academies Press; 2010.
Downloads
Published
2014-09-30
How to Cite
1.
ฬียาพรรณ จ, พีรกุล ย, สิทธิบุศย์ ช. Osteoporosis in HIV-infected patient. Dis Control J [Internet]. 2014 Sep. 30 [cited 2024 Nov. 18];40(3):215-21. Available from: https://he01.tci-thaijo.org/index.php/DCJ/article/view/154185
Issue
Section
Review Article
License
Articles published in the Disease Control Journal are considered as academic work, research or analysis of the personal opinion of the authors, not the opinion of the Thailand Department of Disease Control or editorial team. The authors must be responsible for their articles.
.png){kind=logo}
